NCT04940130View on ClinicalTrials.gov

PfSPZ Vaccine Trial in Malian Children

PHASE2CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 10, 2022

Study Completion Date

December 10, 2022

Conditions
MalariaMalaria,Falciparum
Interventions
BIOLOGICAL

Sanaria® PfSPZ Vaccine

non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).

OTHER

Normal Saline

placebo control- saline

Trial Locations (1)

Unknown

Malaria Research and Training Center, Bamako

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

University of the Sciences, Techniques and Technologies of Bamako

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Sanaria Inc.

INDUSTRY